As Magrolimab AML Studies Chug Along, The Question Becomes How To Combine It
With an FDA hold lifted and enrollment moving quickly, physicians are looking at how to combine magrolimab with other treatments in patients with TP53-mutated AML.
With an FDA hold lifted and enrollment moving quickly, physicians are looking at how to combine magrolimab with other treatments in patients with TP53-mutated AML.